ventograft trial: aza, ven, and dli in patients with mds and aml who have relapsed following allosct
Published 10 months ago • 159 plays • Length 2:17
Download video MP4
Download video MP3
Similar videos
-
4:44
7-year update on a phase ii trial of fixed-duration obinutuzumab, ibrutinib, and venetoclax for cll
-
4:51
the current frontline treatment strategy in multiple myeloma
-
4:22
discover versiti diagnostic labs, clinical trials and biomaterials | versiti
-
5:36
venetoclax and azacitidine in mds patients
-
2:11
update on phase i/ii study of azacitidine, venetoclax and gilteritinib in patients with flt3 aml
-
2:37
maintenance venetoclax and 5-azacytidine in patients with aml
-
1:12
phase i study of ziftomenib with venetoclax or venetoclax/azacitidine or 7 3 in r/r aml
-
1:59
phase i study of pevonedistat, azacitidine, and venetoclax in patients with r/r aml
-
3:03
venetoclax and 5-azacytidine for the treatment of mds and cmml
-
2:20
pevonedistat, azacitidine and venetoclax triplet therapy for aml, mds and cmml
-
1:34
the mutational profile in patients with cll treated with acalabrutinib or ibrutinib
-
2:08
the venice-1 trial: venetoclax monotherapy in r/r cll
-
3:09
bleximenib combined with venetoclax and azacitidine in r/r aml with kmt2a or npm1 alterations
-
1:17
the efficacy of olutasidenib in aml following venetoclax failure
-
0:52
imroz trial updates: isa-vrd versus vrd in patients with ndmm ineligible for transplant
-
5:31
the role of venetoclax in older patients with aml
-
1:36
improve study update: safety and efficacy of venetoclax retreatment in r/r cll
-
3:15
developments in targeted aml therapies: venetoclax, quizartinib & gilteritinib
-
1:54
a novel clinical trial endpoint for acute gvhd
-
3:52
venetoclax & aml
-
1:18
the importance of lymphodepletion, an undervalued component of the car-t therapy cycle
-
3:42
mechanisms of resistance to venetoclax in aml and methods being explored to overcome these
Clip.africa.com - Privacy-policy